Sort   by:  
 Page size 
UnknownSwitching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Not available
S-EPMC7899215 | biostudies-literature
UnknownHIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Not available
S-EPMC6988963 | biostudies-literature
UnknownSWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Not available
S-EPMC3641864 | biostudies-literature
UnknownBictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Not available
S-EPMC10083930 | biostudies-literature
UnknownBictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.
Not available
S-EPMC8116430 | biostudies-literature
Sort   by:  
 Page size